FierceBiotech Names Syros Pharmaceuticals as One of Its “Fierce 15” Biotech Companies of 2015

FierceBiotech Names Syros Pharmaceuticals as One of Its “Fierce 15” Biotech Companies of 2015

September 30, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, the industry pioneer in gene control medicines, today announced that it has been named by FierceBiotech as one of 2015’s Fierce 15 biotechnology companies. The award designates Syros as one of the most promising private companies in the biotech industry.

WBCSD brings together over 200 business leaders to turn ambitious low-carbon targets into action for significant emission reductions

WBCSD brings together over 200 business leaders to turn ambitious low-carbon targets into action for significant emission reductions

September 25, 2015

Over 200 representatives from forward-thinking businesses around the globe are coming together in New York City during Climate Week, where action plans under the Low Carbon Technology Partnerships initiative (LCTPi) will be finalized for presentation at COP21 in Paris this December. The plans will deliver a significant contribution from the business sector to reduce emissions and ensure that the rise in global temperatures remains under the 2°C ceiling.

BIND Therapeutics Announces Pfizer Inc. Exercises Option to Advance Nanoparticle-Based Kinase Inhibitor for Treatment of Solid Tumors

BIND Therapeutics Announces Pfizer Inc. Exercises Option to Advance Nanoparticle-Based Kinase Inhibitor for Treatment of Solid Tumors

September 24, 2015

-- BIND earns $2.5 million option fee for first compound in global collaboration to pursue development and commercialization of novel Accurins --

Syros Pharmaceuticals Licenses Clinical-Stage RARα Agonist to Develop and Commercialize for Genomically-Defined Cancer Populations Identified by Gene Control Platform

Syros Pharmaceuticals Licenses Clinical-Stage RARα Agonist to Develop and Commercialize for Genomically-Defined Cancer Populations Identified by Gene Control Platform

September 24, 2015

- Phase 2 clinical trial in acute myeloid leukemia (AML) / myelodysplastic syndrome (MDS) patients with gene control biomarker discovered by Syros planned in the first half of 2016 -

- Provides validation for proprietary gene control target and biomarker discovery and development platform -

Seventh Sense Biosystems Announces Expansion of Manufacturing Operations and Facilities in Medford, Massachusetts

Seventh Sense Biosystems Announces Expansion of Manufacturing Operations and Facilities in Medford, Massachusetts

September 21, 2015

MEDFORD, Mass.--(BUSINESS WIRE)--Seventh Sense Biosystems, Inc., (7SBio), a leading developer of blood collection and diagnostic platforms, announced today it is expanding its manufacturing operations and relocating its home office.

Syros Pharmaceuticals Appoints Kyle Kuvalanka as Chief Operating Officer

Syros Pharmaceuticals Appoints Kyle Kuvalanka as Chief Operating Officer

September 21, 2015

CAMBRIDGE, Mass.--(BUSINESS WIRE)--Syros Pharmaceuticals, the industry pioneer in gene control, announced today that accomplished industry veteran Kyle Kuvalanka joined the Company as its first Chief Operating Officer. In this newly created role, Mr. Kuvalanka will hold broad management responsibility for finance, business development, new product planning, and other business operations, as well as the Company’s proprietary gene control mapping platform.

Agilent Technologies to Acquire Seahorse Bioscience, Industry Leader in Tools for Measuring Cell Metabolism

Agilent Technologies to Acquire Seahorse Bioscience, Industry Leader in Tools for Measuring Cell Metabolism

September 9, 2015

Acquisition Complements Agilent's Market-Leading Separations and Mass Spectrometry Solutions, Expands Pharma Offerings

SANTA CLARA, Calif., and BILLERICA, Mass., Sept. 9, 2015 Agilent Technologies Inc. (NYSE: A) and Seahorse Bioscience today announced they have signed a definitive agreement under which Agilent will acquire Seahorse Bioscience, a leader in providing instruments and assay kits for measuring cell metabolism and bioenergetics.

Dow, Honeywell and Novomer finalists for PU innovation award

Dow, Honeywell and Novomer finalists for PU innovation award

September 9, 2015

The Center for the Polyurethanes Industry has announced the finalists for the 2015 Polyurethane Innovation Award: Dow Chemical Co., Honeywell International Inc. and Novomer Inc.

The winner will be announced on Oct. 7, the final day of the 2015 Polyurethanes Technical Conference in Orlando, Fla. The three commercial technologies will be presented during the opening session on Oct. 5. Attendees at the opening session will vote, and that tally will be combined with scores from professional judges to determine the winner.

The three finalist innovations are:  

Visterra, Inc. and Serum Institute of India Ltd. Announce Collaboration to Advance VIS513, a Monoclonal Antibody in Development for the Treatment of Dengue, in the Indian Subcontinent

Visterra, Inc. and Serum Institute of India Ltd. Announce Collaboration to Advance VIS513, a Monoclonal Antibody in Development for the Treatment of Dengue, in the Indian Subcontinent

September 9, 2015

CAMBRIDGE, Mass. & PUNE, India--(BUSINESS WIRE)--Visterra, Inc., a clinical-stage biotechnology company that uses its proprietary technology platform to identify unique disease targets and design novel therapeutics for infectious diseases, and Serum Institute of India Ltd. (Serum Institute), a global leader in vaccine development and manufacturing, today announced that the companies have entered into a license agreement for the development, manufacture and commercialization of VIS513 in the Indian subcontinent countries.

Flagship Ventures Adds Internal IP Counsel

Flagship Ventures Adds Internal IP Counsel

September 9, 2015

Biotech industry veteran Leda Trivinos to lead expansion of firm’s internal innovation and patenting program

Cambridge, Mass., Sept. 9, 2015/PRNewswire/ -- Flagship Ventures, a leading venture capital and venture creation firm focused on innovations in healthcare and sustainability, announced it has hired Leda Trivinos, Ph.D., as Partner, Intellectual Property. Trivinos will play a key role as Flagship scales the company creation activities of its VentureLabs innovation foundry.